On Wednesday our $13 billion dollar man, Dr. Patrick Soon-Shiong, announced the creation of another new company under the NantWorks umbrella. It’s called NantCell.

Dr. Soon-Shiong has been unstoppable recently, purchasing, merging, and creating cutting-edge technology companies that are changing.

NantCell is taking a smarter approach to cancer fighting by focusing on molecular-based screening factors to better match up cancer patients with treatments. Patients will go through a comprehensive “omic” analysis on their DNA, RNA and protein.

These patients will be treated on the resulting molecular profile to maximize clinical outcome and minimize side-effects. The company’s mission is to leverage advanced computing technology in order to replace the standard method of clinical trial design of “trial and error” with a level of quantitative predictability.

NantCell has entered into a licensing agreement with Amgen (Nasdaq:AMGN) for the exclusive rights to develop and commercialize AMG 479, a fully human monoclonal antibody that targets Type 1 insulin-like growth factor receptors that kill tumors.

AMG 479 actually failed in a Phase III trial for treating advanced pancreatic cancer in 2012, but NantCell believes that with its molecular profiling technology, it’ll be able to find the ideal patients for the therapy to make it a success.

NantCell is also a joint venture with Sorrento Therapeutics (Nasdaq:SRNE). As you may recall from my previous article, Dr. Soon-Shiong took a sizable stake in Sorrento in December, almost doubling the share price to $8. After another deal between Soon-Shiong, Sorrento and Conkwest was announced in late December, this rocketed Sorrento share price above $10.

Now with the third announcement between Soon-Shiong and Sorrento hitting the streets on Wednesday this week, Sorrento share price has benefited greatly, rising another 12% on Wednesday. Overall, Sorrento share price has risen 254% in the last 3 months.

Nantwork Chart

See larger image

Investors know that Patrick Soon-Shiong is continuing to methodically add truly disruptive technology companies to the cancer fighting space under his NantWorks conglomerate. Since NantWorks and NantCell are not publicly traded, the next best option is investing in the publicly traded companies they are partnering with.

I currently track trends surrounding healthcare and biotech utilizing my Social Media Collective Intelligence system and provide alerts in my Biotech Intel Trader service. If you’re interested in learning more, check out my trading service here.

As always, I will continue to monitor the market’s social media collective intelligence and keep you updated on the latest trends.

Happy Hunting,

Strategies Fit for Today's Market

Investing is no longer a set-it-and-forget-it affair. If you’re still using that outdated approach in today’s irrational markets, you’re setting yourself up for massive losses and a difficult retirement. There’s a much… Read More>>
Ben Benoy
Ben Benoy is a veteran of the U.S. Marine Corps and has been an active retail trader since 2006. He identifies investment opportunities based on key social media trends. He first identified the concept in 2008 and has since developed a tool for tracking investment “chatter” between social media users. His proprietary Social Media Stock Sentiment system has developed into a state-of-the-art platform that identifies and classifies chatter about stocks through algorithms and other indicators to forecast stock-price direction. Ben’s track record speaks for itself — over the past 12 months, his system boasts a win rate of 82.2% on 112 stock trades.